L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA)

Gynecologic Oncology

Volumn 141, Issue 2, 2016, Pages 336-340

  Dellinger, Thanh H ^a   Smith, David D ^b   Ouyang, Ching ^a   Warden, Charles D ^a   Williams, John C ^a   Han, Ernest S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Endometrial cancer; L1CAM; TCGA

Indexed keywords

NERVE CELL ADHESION MOLECULE L1; CD56 ANTIGEN; NCAM1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GENOME ATLAS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENOME; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; BIOSYNTHESIS; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; BIOMARKERS, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS;

EID: 84958213895     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.003     Document Type: Article

References (24)

1. Siegel R.L., Miller K.D., and Jemal A. Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29
2. Obel J.C., Friberg G., and Fleming G.F. Chemotherapy in endometrial cancer Clin. Adv. Hematol. Oncol. 4 2006 459 468
3. Mechtersheimer S., Gutwein P., Agmon-Levin N., Stoeck A., Oleszewski M., and et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins J. Cell Biol. 155 2001 661 673
4. Gast D., Riedle S., Schabath H., Schlich S., Schneider A., and et al. L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas Int. J. Cancer 115 2005 658 665
5. Gast D., Riedle S., Issa Y., Pfeifer M., Beckhove P., and et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies Oncogene 27 2008 1281 1289
6. Arlt M.J., Novak-Hofer I., Gast D., Gschwend V., Moldenhauer G., and et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment Cancer Res. 66 2006 936 943
7. Colas E., Pedrola N., Devis L., Ertekin T., Campoy I., and et al. The EMT signaling pathways in endometrial carcinoma Clin. Transl. Oncol. 14 2012 715 720
8. Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., and et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas Lancet 362 2003 869 875
9. A.G. Zeimet, SA-A, and et al. Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer J. Clin. Oncol. 29 2011 (Abstract 5091)
10. Bosse T., Nout R.A., Stelloo E., Dreef E., Nijman H.W., and et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results Eur. J. Cancer 50 2014 2602 2610
11. Sebens Muerkoster S., Kotteritzsch J., Geismann C., Gast D., Kruse M.L., and et al. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma Int. J. Oncol. 34 2009 243 253
12. Geismann C., Arlt A., Bauer I., Pfeifer M., Schirmer U., and et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells Int. J. Oncol. 38 2011 257 266
13. Gutwein P., Stoeck A., Riedle S., Gast D., Runz S., and et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells Clin. Cancer Res. 11 2005 2492 2501
14. Schirmer U., Fiegl H., Pfeifer M., Zeimet A.G., Muller-Holzner E., and et al. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens BMC Cancer 13 2013 156
15. Gavert N., Conacci-Sorrell M., Gast D., Schneider A., Altevogt P., and et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers J. Cell Biol. 168 2005 633 642
16. Pfeifer M., Schirmer U., Geismann C., Schafer H., Sebens S., and et al. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions BMC Mol. Biol. 11 2010 64
17. Huszar M., Pfeifer M., Schirmer U., Kiefel H., Konecny G.E., and et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas J. Pathol. 220 2010 551 561
18. Kiefel H., Bondong S., Hazin J., Ridinger J., Schirmer U., and et al. L1CAM: a major driver for tumor cell invasion and motility Cell Adhes. Migr. 6 2012 374 384
19. Friedli A., Fischer E., Novak-Hofer I., Cohrs S., Ballmer-Hofer K., and et al. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor Int. J. Biochem. Cell Biol. 41 2009 1572 1580
20. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497: 67-73.
21. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., and et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 92 2004 744 751
22. Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., and et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation J. Natl. Cancer. Inst. 2013
23. Van Gool I.C., Stelloo E., Nout R.A., Nijman H.W., Edmondson R.J., and et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer Mod. Pathol. 29 2016 174 181
24. Visser N.C., Bulten J., van der Wurff A.A., Boss E.A., Bronkhorst C.M., and et al. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study BMC Cancer 15 2015 487